BioSpace News Archive

Announced the pricing of an underwritten public offering of 388,403 shares of its common stock

Levo Therapeutics Inc. announced today that JCI Insight has published the results of a Phase 2 study of intranasal carbetocin (LV-101).

Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA analysis, announces a powerful new kidney transplant rejection biomarker and study results in collaboration with the University of California, San Francisco, a recognized leader in transplantation care. The data demonstrates superior performance of its massively-multiplexed PCR (mmPCR) technology for detecting acute rejection in kidney transplant patients.

Vertex Pharmaceuticals Incorporated today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize.

Program Designed to Support U.S. Regulatory Filing of IW-3718 as Potential Treatment for Patients Who Continue to Suffer From GERD Despite Receiving Standard of Care.

Up to 48 subjects will be enrolled including 24 healthy volunteers and 24 subjects with type 1 diabetes.

FDA inspectors will review the video recordings of smoke study tests to verify unidirectional airflow and sweeping action over and away from the product.

DiaSorin Molecular LLC announced today that the company has received FDA clearance extending the sample type claims of its Simplexa® HSV 1 & 2 Direct assay.

PHARNEXT SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced an update from its ongoing Phase 3 clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A) in adults. Top-line results from the pivotal PLEO-CMT study are now expected by October 2018.

The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market NOCDURNA®.